Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT) after TKR were higher in Taiwan than other countries in Asia. Therefore, the usage of prophylactic antithrombotics should be considered. The efficacy and safety of Xarelto (Rivaroxaban) for preventing venous thromboembolism has been proved. However, there is a lack of study using prospective design to evaluate the efficacy and safety of Xarelto after THR and TKR for Taiwanese. In this study, we use a randomized controlled trial design comparing the incidence of DVT, pulmonary embolism, and complications between intervention and control groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chiayi Christian Hospital
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Undergo total knee replacement or total hip replacement

Exclusion Criteria:

• Recent antithrombotics use

• A history of a coagulopathy

• Recent thromboembolic disease

• Preoperative deep vein thrombosis screening presents positive

• Age below 20